| Name | Title | Contact Details |
|---|
Driven by a vision to liberate patients from degenerative disease, BlueRock Therapeutics is ushering in a new era of cell-based medicines. Founded in 2016, BlueRock and its team of preeminent scientists are pioneering cell therapies that restore critical natural functions in the body, with an initial focus on severe brain and heart conditions. BlueRock`s culture is defined by scientific transparency, the highest ethical standards and an urgency to bring transformative treatments to all who would benefit.
GN ReSound is the undisputed technology leader in the global hearing instrument market and is one of several divisions of GN Great Nordic. To learn more about our parent company, Great Nordic, please click on the link below.
Welcome to LunchboxWax, a place that proves that chic and cheeky do, in fact, co-exist. Our refined, unique speed-waxing technique means smooth skin is just minutes away. You won`t be at LunchboxWax long, but while you`re here, you`ll feel like you`re the only one who matters. Because to us, you are. Great things happen when you choose to do one thing and do it well. That`s why we believe our Lunchbox waxologists are the best. They`re committed to their craft and your happiness. It`s all they do. Just like we handpick our waxologists, we assemble other experts to make our business run as smooth as your skin after a LunchboxWax Brazilian. Yep, we just said that. Our business formula works, and we`re excited to share it through the LunchboxWax Franchise System.
Autumn View Gardens is a Ellisville, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.